Aug 6 (Reuters) - Prothena Corporation PLC PRTA.O:
PROTHENA ANNOUNCES THAT NOVO NORDISK WILL ADVANCE CORAMITUG (FORMERLY PRX004) INTO PHASE 3 DEVELOPMENT FOR ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY
PROTHENA CORPORATION: UNDER AGREEMENT, CO IS ELIGIBLE TO RECEIVE UP TO $1.2 BILLION DOLLARS UPON ACHIEVEMENT OF CLINICAL DEVELOPMENT & SALES MILESTONES
Source text: ID:nBw6ylMXVa
Further company coverage: PRTA.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。